(MedPage Today) — Patients with advanced non-small cell lung cancer who received immunochemotherapy in the morning or early afternoon had better survival outcomes compared with patients who received treatment later in the day, a phase III randomized…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
